Document 1080
 DOCN  M9471080
 TI    Cost-benefit analysis of bone marrow (BM) immunophenotyping (IP) in the
       staging of non-Hodgkin's lymphoma (NHL) (Meeting abstract).
 DT    9409
 AU    Denes AE; Hathaway C; St. John's Mercy Medical Center, St. Louis, MO
       63141
 SO    Proc Annu Meet Am Soc Clin Oncol; 13:A1332 1994. Unique Identifier :
       AIDSLINE ICDB/94601328
 AB    BM IP is often used in conjunction with light microscopy (LM) in the
       staging evaluation of patients (pts) with NHL. We conducted a
       retrospective review of 50 BM staging procedures to determine the
       sensitivity of IP in the detection of occult BM involvement in pts with
       NHL. IP was performed on an Epics II Profile flow cytometer (Coulter)
       using a panel of 6-15 antibodies (n=10). Pts ranged in age from 20-86 yr
       and the male:female ratio was 23:27. Results are summarized in a table.
       In only one pt was a clonal proliferation detected by IP that was not
       apparent by LM. This was a B cell lymphoproliferative disorder in an
       HIV+ pt with fever and diffuse adenopathy. The total cost of IP in these
       50 pts was 49,824 dollars (range 576-1344 dollars, m=996 dollars/pt
       sample). These results indicate that IP is not more sensitive than LM in
       the detection of BM involvement by NHL. The routine use of BM IP in the
       staging evaluation of pts with NHL is not recommended.
 DE    Adult  Aged  Aged, 80 and over  Bone Marrow/*PATHOLOGY  Cost-Benefit
       Analysis  Female  Human  Immunophenotyping/*ECONOMICS  Lymphoma,
       Non-Hodgkin's/ECONOMICS/*PATHOLOGY  Male  Middle Age  Neoplasm Staging
       Retrospective Studies  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).